Breast Cancer Clinical Trial

National Breast Cancer and Lymphedema Registry

Summary

The purpose of the National Breast Cancer Lymphedema Registry is to collect health information in order to study the lymphedema as a complication of breast cancer treatment. The investigators hope to learn whether early diagnosis will help to prevent lymphedema or, if it does occur, to reduce the severity.

View Full Description

Full Description

Historically, breast cancer-associated lymphedema has been relatively ignored, with mis-diagnosis, late diagnosis, and failure to treat. The condition has a measurable, substantial impact on patient function and perceived quality of life (QOL). Recent pilot studies suggest that interventions that are designed to facilitate early diagnosis and preventive strategies have a major impact on the incidence and severity of disease burden. This registry is designed to prospectively capture the relevant data to document the impact of preemptive diagnostic and treatment strategies.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Breast cancer survivorship

Exclusion Criteria:

Age < 18 years old

Study is for people with:

Breast Cancer

Estimated Enrollment:

549

Study ID:

NCT01580800

Recruitment Status:

Terminated

Sponsor:

Stanley Rockson

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Stanford University School of Medicine
Stanford California, 94305, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

549

Study ID:

NCT01580800

Recruitment Status:

Terminated

Sponsor:


Stanley Rockson

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider